Vinaora Nivo SliderVinaora Nivo Slider
Important preclinical study within the TBI program
NeuroVive initiates the first study in the preclinical program for traumatic brain injury (TBI) in collaboration with University of Pennsylvania.
Rights issue for continued development of the project portfolio
NeuroVive’s aim is to complete the two ongoing phase II studies CiPRICS and CHIC before the end of 2016.

Financial Calendar

2016 May 31

2016 Aug 18

2016 Nov 22


2016 Jun 6 - 9
San Francisco, USA

2016 Jun 26 - 30
Lexington, Kentucky

About Neurovive

NeuroVive is a pharmaceutical company focusing on mitochondrial medicine, a highly promising area set to create a paradigm shift in drug development. NeuroVive has positioned itself as a cutting-edge company in the area with two projects in the clinical phase and three in the pre-clinical phase. At NeuroVive, we’re focusing on continuously developing the platform of pharmaceutical products the company’s operations are based on.

» Learn more